Alzheimer’s Disease (Central Nervous System) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease (Central Nervous System) – Drugs In Development, 2021, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease (Central Nervous System) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 23, 62, 86, 1, 4, 358, 178 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 3, 107 and 52 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

1st Bio Therapeutics Inc

2A Pharma AB

4B Technologies (Suzhou) Co Ltd

4P-Pharma SAS

AB Science SA

Abaxy Sprl

AbbVie Inc

Abrexa Pharmaceuticals Inc

AC Immune SA

Acadia Pharmaceuticals Inc

Accuitis Pharmaceuticals Inc

Acelot Inc

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Addex Therapeutics Ltd

ADEL Inc

Adocia SAS

ADRx Inc

Aerobyx LLC

Avidin Biotechnology Ltd

Avineuro Pharmaceuticals Inc

Axon Neuroscience SE

Axxam SpA

AZTherapies Inc

Berg LLC

BeyondBio Inc

Bio-Pharm Solutions Co Ltd

BioArctic AB

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

Biom Therapeutics LLC

Biorchestra Ltd

BioSplice Therapeutics Inc

BioVie Inc

BioXcel Therapeutics Inc

Bisichem Co Ltd

Boehringer Ingelheim International GmbH

Bolden Therapeutics Inc

Bolder Biotechnology Inc

Boryung Pharmaceutical Co Ltd

Brain Innovation Co Ltd

BrainStorm Cell Therapeutics Inc

Brainvectis SAS

Corium Inc

Cortexyme Inc

Cortice Biosciences Inc

Covalent Bioscience Inc

Coya Therapeutics Inc

Creative Bio-Peptides Inc

Crossbeta Biosciences BV

CuroNZ Ltd

Cyclerion Therapeutics Inc

Cyclo Therapeutics Inc

CycloLab Cyclodextrin Research and Development Laboratory Ltd

Dadang & BIO Co Ltd

Daewoong Pharmaceutical Co Ltd

Immunwork Inc

Inmune Bio Inc

InnoBioscience LLC

InnoPharmaScreen Inc

Kwang Dong Pharmaceutical Co Ltd

Kyowa Kirin Co Ltd

Lacerta Therapeutics Inc

Landos Biopharma Inc

Lauren Sciences LLC

Lead Discovery Center GmbH

LEXEO Therapeutics LLC

Libella Gene Therapeutics

Light Chain Bioscience

Longeveron Inc

LSL Neurosciences LLC

Lyndra Therapeutics Inc.

MetrioPharm AG

MetVital Inc

MGC Pharmaceuticals Ltd

Mindset Pharma Inc

Mission Therapeutics Ltd

Mitoconix Bio Ltd

Modag GmbH

Montisera Ltd

NAL Pharmaceuticals Ltd

Nanomerics Ltd

NatureWise Biotech & Medicals Corp

Neonc Technologies Inc

NeoNeuro SAS

NeoProgen Inc

NervGen Pharma Corp

NeuExcell Therapeutics Inc

Neuracle Science Co Ltd

Oleolive LLC

Oligomerix inc

OncoSynergy Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Orpheris Inc

Orphi Therapeutics Inc

Oryzon Genomics SA

OTR3 SAS

Overseas Pharmaceuticals Ltd

Oxstem Ltd

P2D Inc

Palisade Bio, Inc

Panorama Researchama Research

Paramag Biosciences

Transposon Therapeutics Inc

Treeway BV

Treventis Corp

Tria Bioscience Corp

Triplet Therapeutics Inc

TrueBinding Inc

UCB SA

Uni-Bio Science Group Ltd

Unity Biotechnology Inc

USA Elixiria Biotech Inc

Vaccinex Inc

Vanworld Pharmaceutical (Rugao) Company Ltd

Varinel Inc

Vaxxinity Inc

VectorY Therapeutics Inc

VFP Therapies

Videns Incorp Ltd

Virogenics Inc

Vitruvian Biomedical Inc

Vivoryon Therapeutics NV

Vivreon Biosciences LLC

Voronoi Group

Voyager Therapeutics Inc

Vybion Inc

Whan In Pharm Co Ltd

Wren Therapeutics Ltd

Xcelthera INC

Xenexus Pharmaceuticals Pty Ltd

Xigen SA

Xonovo Inc

Yasham P2D Lifesciences Pvt Ltd

Yuhan Corp

Yuma Therapeutics Corp

Yumanity Therapeutics Inc

Zensun (Shanghai) Sci & Tech Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Zhejiang Huahai Pharmaceutical Co Ltd

Zhittya Genesis Medicine Inc

ZZ Biotech LLC

Table of Contents

Table of Contents

Introduction

Alzheimer's Disease - Overview

Alzheimer's Disease - Therapeutics Development

Alzheimer's Disease - Therapeutics Assessment

Alzheimer's Disease - Companies Involved in Therapeutics Development

Alzheimer's Disease - Drug Profiles

Alzheimer's Disease - Dormant Projects

Alzheimer's Disease - Discontinued Products

Alzheimer's Disease - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Alzheimer's Disease, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Alzheimer's Disease – Pipeline by 1st Bio Therapeutics Inc, 2021

Alzheimer's Disease – Pipeline by 2A Pharma AB, 2021

Alzheimer's Disease – Pipeline by 4B Technologies (Suzhou) Co Ltd, 2021

Alzheimer's Disease – Pipeline by 4P-Pharma SAS, 2021

Alzheimer's Disease – Pipeline by AB Science SA, 2021

Alzheimer's Disease – Pipeline by Abaxy Sprl, 2021

Alzheimer's Disease – Pipeline by AbbVie Inc, 2021

Alzheimer's Disease – Pipeline by Abrexa Pharmaceuticals Inc, 2021

Alzheimer's Disease – Pipeline by AC Immune SA, 2021

Alzheimer's Disease – Pipeline by Acadia Pharmaceuticals Inc, 2021

Alzheimer's Disease – Pipeline by Accuitis Pharmaceuticals Inc, 2021

Alzheimer's Disease – Pipeline by Acelot Inc, 2021

Alzheimer's Disease – Pipeline by Actinogen Medical Ltd, 2021

Alzheimer's Disease – Pipeline by Acumen Pharmaceuticals Inc, 2021

Alzheimer's Disease – Pipeline by Addex Therapeutics Ltd, 2021

Alzheimer's Disease – Pipeline by ADEL Inc, 2021

Alzheimer's Disease – Pipeline by Adocia SAS, 2021

Alzheimer's Disease – Pipeline by ADRx Inc, 2021

Alzheimer's Disease – Pipeline by Aerobyx LLC, 2021

Alzheimer's Disease – Pipeline by Aeton Therapeutics Inc, 2021

Alzheimer's Disease – Pipeline by AfaSci Inc, 2021

Alzheimer's Disease – Pipeline by AIBIOS Co Ltd, 2021

Alzheimer's Disease – Pipeline by Akome Biotech Ltd, 2021

Alzheimer's Disease – Pipeline by Alector Inc, 2021

Alzheimer's Disease – Pipeline by Alfasigma SpA, 2021

Alzheimer's Disease – Pipeline by Alkahest Inc, 2021

Alzheimer's Disease – Pipeline by Alkermes Plc, 2021

Alzheimer's Disease – Pipeline by Allyx Therapeutics Inc, 2021

Alzheimer's Disease – Pipeline by Alnylam Pharmaceuticals Inc, 2021

Alzheimer's Disease – Pipeline by AlphaCognition Inc, 2021

Alzheimer's Disease – Pipeline by Alsonex Pty Ltd, 2021

Alzheimer's Disease – Pipeline by Longeveron Inc, 2021

Alzheimer's Disease – Pipeline by LSL Neurosciences LLC, 2021

Alzheimer's Disease – Pipeline by Lyndra Therapeutics Inc., 2021

Alzheimer's Disease – Pipeline by Madera BioSciences Inc, 2021

Alzheimer's Disease – Pipeline by Magnolia Neurosciences Corp, 2021

Alzheimer's Disease – Pipeline by ManRos Therapeutics, 2021

Alzheimer's Disease – Pipeline by MapLight therapeutics Inc, 2021

Alzheimer's Disease – Pipeline by MaxiVAX SA, 2021

Alzheimer's Disease – Pipeline by MD Healthcare Inc, 2021

Alzheimer's Disease – Pipeline by MDimune Inc, 2021

Alzheimer's Disease – Pipeline by MedBiome Inc, 2021

Alzheimer's Disease – Pipeline by Medesis Pharma SA, 2021

Alzheimer's Disease – Pipeline by Medifron DBT Co Ltd, 2021

Alzheimer's Disease – Pipeline by medilabo RFP Inc, 2021

Alzheimer's Disease – Pipeline by MEDRx Co Ltd, 2021

Alzheimer's Disease – Pipeline by MegaNano BioTech Inc, 2021

Alzheimer's Disease – Pipeline by MEI Pharma Inc, 2021

Alzheimer's Disease – Pipeline by Mercia Pharma Inc, 2021

Alzheimer's Disease – Pipeline by Merck & Co Inc, 2021

Alzheimer's Disease – Pipeline by MetiMedi Pharmaceuticals Co Ltd, 2021

Alzheimer's Disease – Pipeline by MetrioPharm AG, 2021

Alzheimer's Disease – Pipeline by MetVital Inc, 2021

Alzheimer's Disease – Pipeline by MGC Pharmaceuticals Ltd, 2021

Alzheimer's Disease – Pipeline by Mindset Pharma Inc, 2021

Alzheimer's Disease – Pipeline by Mission Therapeutics Ltd, 2021

Alzheimer's Disease – Pipeline by Mitoconix Bio Ltd, 2021

Alzheimer's Disease – Pipeline by Modag GmbH, 2021

Alzheimer's Disease – Pipeline by Montisera Ltd, 2021

Alzheimer's Disease – Pipeline by NAL Pharmaceuticals Ltd, 2021

Alzheimer's Disease – Pipeline by Nanomerics Ltd, 2021

Alzheimer's Disease – Pipeline by NatureWise Biotech & Medicals Corp, 2021

Alzheimer's Disease – Pipeline by Neonc Technologies Inc, 2021

Alzheimer's Disease – Pipeline by NeoNeuro SAS, 2021

Alzheimer's Disease – Pipeline by NeoProgen Inc, 2021

Alzheimer's Disease – Pipeline by NervGen Pharma Corp, 2021

Alzheimer's Disease – Pipeline by NeuExcell Therapeutics Inc, 2021

Alzheimer's Disease – Pipeline by Neuracle Science Co Ltd, 2021

Alzheimer's Disease – Pipeline by Neuraly Inc, 2021

List of Figures

List of Figures

Number of Products under Development for Alzheimer's Disease, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports